Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

Lung CARET
138
Feng, ZidingFred Hutchinson Cancer Research Center
Annexin, LAMR1, PGP, Annexin 1 and SOX2, APEX1, CYGB, DAPK1, EFEMP1, Halling 4-marker LAVysion lung cancer probe set, MPG, OGG1, TCF21
No design specified.
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

Aim 1: To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis. Aim 2: To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type. Aim 3: To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Natural Array technique

Version 5.1.0